Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06700213 · ClinicalTrials.gov registry record
Guideline Directed Medical Therapy in Patients With Heart Failure
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 300
- Enrollment target
NCT06700213: Completed study, sponsored by Massachusetts General Hospital.
NCT06700213 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06700213 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
The TEAM-MGH study will formerly evaluate impact of the GDMT Clinic versus matched usual care patients on the proportion of GDMT administration over a 12 week period in approximately 300 total patients with HF across the spectrum of LVEF (with a minimum of 150 with HFrEF). The study will also assess impact of the GDMT Clinic on health status, functional capacity, biomarker profiles, cardiac remodeling and cardiovascular events.
Primary Outcome
Effect of GDMT Clinic versus Usual Care on administration of GDMT for HF.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-09-22 |
| Est. Completion | 2025-09-22 |
What the finished NCT06700213 record still lists
NCT06700213 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06700213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06700213 about?
NCT06700213 is a clinical study titled "Guideline Directed Medical Therapy in Patients With Heart Failure". The TEAM-MGH study will formerly evaluate impact of the GDMT Clinic versus matched usual care patients on the proportion of GDMT administration over a 12 week period in approximately 300 total patients with HF across the spectrum of LVEF (with a minimum of 150 with HFrEF). The study will also assess...
What is the current status of trial NCT06700213?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2023-09-22. Estimated completion is 2025-09-22.
Who is sponsoring clinical trial NCT06700213?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI